Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by
the US Food and Drug Administration for the treatment of patients with locally advanced or …

The human skin hosts millions of bacteria, fungi, archaea, and viruses. These skin microbes
play a crucial role in human immunological and physiological functions, as well as the …

The new landscape of treatments for metastatic clear cell renal carcinoma (mRCC) is
constantly expanding, but it is associated with the emergence of novel toxicities, adding to …

Objectives Advances in science and technology have meant there are numerous treatment
options available for people with advanced breast cancer (ABC). However, each therapeutic …

Background: Management of cancer treatment–related skin toxicities can minimize treatment
disruptions and improve patient well-being. Objectives: This guideline aims to support …

Background: Many patients with locally advanced or metastatic urothelial carcinoma (mUC)
need additional treatment options beyond PD-1 or PD-L1 inhibitors and platinum-based …

Introduction Xerosis is a common skin side effect of current anticancer therapies, including
chemotherapy, targeted therapy, radiotherapy, and hormonotherapy. We evaluated the …

Introduction Enfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for
bladder cancer patients following post-chemotherapy and immunotherapy. This study …

Simple Summary Many cancer treatments, including chemotherapy, targeted therapy,
immunotherapy, and radiotherapy, can cause skin side effects. These are called …

Background Systemic chemotherapy and targeted agents are associated with various
cutaneous toxicities. Even though cutaneous toxicities are manageable, it often results in …